Compare CPNG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPNG | RPRX |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3B | 25.9B |
| IPO Year | 2021 | 2020 |
| Metric | CPNG | RPRX |
|---|---|---|
| Price | $16.78 | $57.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $32.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 18.3M | 2.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | ★ $34,534,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $13.15 | $38.63 |
| Revenue Next Year | $13.75 | $4.73 |
| P/E Ratio | ★ N/A | $85.33 |
| Revenue Growth | ★ 14.09 | 5.06 |
| 52 Week Low | $14.92 | $34.63 |
| 52 Week High | $34.08 | $60.44 |
| Indicator | CPNG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 52.10 |
| Support Level | $14.98 | $54.95 |
| Resistance Level | $16.91 | $58.84 |
| Average True Range (ATR) | 0.56 | 1.30 |
| MACD | 0.03 | -0.21 |
| Stochastic Oscillator | 65.21 | 37.99 |
Coupang is South Korea's largest e-commerce platform that sells both owned and third-party inventory. Headquartered in the US, Coupang operates e-commerce businesses mainly in South Korea and Taiwan. The company has built an integrated logistics network that covers the entirety of South Korea, with extensive fulfillment centers that ensure timely delivery, even for orders placed seconds before midnight. Outside of its bread-and-butter e-commerce business, Coupang has expanded into Rocket delivery services to third-party merchants (fulfillment and logistics by Coupang), online grocery delivery Rocket Fresh, online meal delivery (Eats), e-commerce in Taiwan, luxury e-commerce (Farfetch), and travel.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.